EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) significantly improves the survival time of advanced non-small cell lung cancer (NSCLC) patients with sensitive EGFR mutation [1, 2].